Changes coming to preferred products for infliximab (reference product Remicade®) for Medicare Advantage members, starting April 1

For dates of service on or after April 1, 2022, we're making the following changes to the medications designated as preferred and nonpreferred infliximab products (reference product Remicade):

This change affects Medicare Plus BlueSM and BCN AdvantageSM members.

Here's what you need to know when prescribing these products:

All nonpreferred products, including Renflexis, require prior authorization for dates of service on or after April 1, 2022.

Submitting requests for prior authorization

Here's how to submit prior authorization requests for preferred products and for nonpreferred products.

List of requirements

For a list of requirements related to drugs covered under the medical benefit, please see the Medical Drug and Step Therapy Prior Authorization List for Medicare Plus Blue PPO and BCN Advantage members (PDF).

We'll update the list to reflect this change prior to the effective date.

Posted: January 2022
Lines of business: Blue Cross Blue Shield of Michigan and Blue Care Network